Overview

Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer

Status:
Completed

Trial end date:
2008-10-01

Target enrollment:

Participant gender:

Summary

To compare the anti-tumour effects as measured by changes in various biomarkers, of a combination of Faslodex and Arimidex with Faslodex alone and Arimidex alone in postmenopausal women patients with primary breast cancer who are awaiting curative-intent surgery.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Anastrozole
Estradiol
Fulvestrant